166 related articles for article (PubMed ID: 35022929)
1. Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.
Salvatori R; Maffei P; Webb SM; Brue T; Loftus J; Valluri SR; Gomez R; Wajnrajch MP; Fleseriu M
Pituitary; 2022 Jun; 25(3):420-432. PubMed ID: 35022929
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
[TBL] [Abstract][Full Text] [Related]
3. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
[TBL] [Abstract][Full Text] [Related]
4. Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY.
van der Lely AJ; Jönsson P; Wilton P; Åkerblad AC; Cara J; Ghigo E
Eur J Endocrinol; 2016 Oct; 175(4):239-45. PubMed ID: 27401863
[TBL] [Abstract][Full Text] [Related]
5. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.
Sievers C; Baur DM; Schwanke A; Buchfelder M; Droste M; Mann K; Stalla GK
Pituitary; 2015 Dec; 18(6):916-23. PubMed ID: 26224528
[TBL] [Abstract][Full Text] [Related]
6. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.
Brue T; Lindberg A; Jan van der Lely A; Akerblad AC; Koltowska-Häggström M; Gomez R; Droste M; Hey-Hadavi J; Strasburger CJ; Camacho-Hübner C
Endocrine; 2019 Mar; 63(3):563-572. PubMed ID: 30474822
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
8. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
[TBL] [Abstract][Full Text] [Related]
9. Brazilian multicenter study on pegvisomant treatment in acromegaly.
Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.
Buchfelder M; van der Lely AJ; Biller BMK; Webb SM; Brue T; Strasburger CJ; Ghigo E; Camacho-Hubner C; Pan K; Lavenberg J; Jönsson P; Hey-Hadavi JH
Eur J Endocrinol; 2018 Dec; 179(6):419-427. PubMed ID: 30325178
[TBL] [Abstract][Full Text] [Related]
11. How to improve effectiveness of pegvisomant treatment in acromegalic patients.
Ragonese M; Grottoli S; Maffei P; Alibrandi A; Ambrosio MR; Arnaldi G; Bianchi A; Puglisi S; Zatelli MC; De Marinis L; Ghigo E; Giustina A; Maffezzoni F; Martini C; Trementino L; Cannavo S
J Endocrinol Invest; 2018 May; 41(5):575-581. PubMed ID: 29080965
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
13. Soluble Klotho: a possible predictor of quality of life in acromegaly patients.
Coopmans EC; El-Sayed N; Frystyk J; Magnusson NE; Jørgensen JOL; van der Lely AJ; Janssen JAMJL; Muhammad A; Neggers SJCMM
Endocrine; 2020 Jul; 69(1):165-174. PubMed ID: 32333268
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
15. Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes.
Vila G; Luger A; van der Lely AJ; Neggers SJCMM; Webb SM; Biller BMK; Valluri S; Hey-Hadavi J
Front Endocrinol (Lausanne); 2020; 11():577173. PubMed ID: 33329385
[TBL] [Abstract][Full Text] [Related]
16. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy in acromegaly patients treated with pegvisomant.
van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
[TBL] [Abstract][Full Text] [Related]
18. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
Grottoli S; Bianchi A; Bogazzi F; Bona C; Carlsson MO; Colao A; Dassie F; Giampietro A; Gomez R; Granato S; Maffei P; Pivonello R; Prencipe N; Ragonese M; Urbani C; Cannavò S
J Endocrinol Invest; 2022 Aug; 45(8):1535-1545. PubMed ID: 35359232
[TBL] [Abstract][Full Text] [Related]
19. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
20. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]